Format

Send to

Choose Destination
Mol Cancer. 2015 Feb 15;14:40. doi: 10.1186/s12943-015-0312-6.

Drug sensitivity in cancer cell lines is not tissue-specific.

Author information

1
Joint IRB-BSC-CRG Program in Computational Biology, Institute for Research in Biomedicine (IRB Barcelona), c/Baldiri i Reixac 10-12, Barcelona, 08028, Catalonia, Spain. samira.jaeger@irbbarcelona.org.
2
Joint IRB-BSC-CRG Program in Computational Biology, Institute for Research in Biomedicine (IRB Barcelona), c/Baldiri i Reixac 10-12, Barcelona, 08028, Catalonia, Spain. miquel.duran@irbbarcelona.org.
3
Joint IRB-BSC-CRG Program in Computational Biology, Institute for Research in Biomedicine (IRB Barcelona), c/Baldiri i Reixac 10-12, Barcelona, 08028, Catalonia, Spain. patrick.aloy@irbbarcelona.org.
4
Institució Catalana de Recerca i Estudis Avançats (ICREA), Pg. Lluís Companys 23, Barcelona, 08010, Catalonia, Spain. patrick.aloy@irbbarcelona.org.

Abstract

BACKGROUND:

Cancer cell lines have a prominent role in the initial stages of drug discovery, facilitating high-throughput screening of potential drugs. However, their clinical relevance remains controversial.

FINDINGS:

We assess whether drug sensitivity in cancer cell lines is able to discriminate tissue specificity. We find that cancer-specific drugs do not show higher efficacies in cell lines representing the respective tissues. Even when considering distinct cancer subtypes and targeted therapies, most drugs are evenly effective/ineffective throughout all cell lines.

CONCLUSIONS:

To get the most out of cell line panels, it will be necessary to look into their molecular characteristics, and integrate them into systems biology frameworks.

PMID:
25881072
PMCID:
PMC4359490
DOI:
10.1186/s12943-015-0312-6
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for BioMed Central Icon for PubMed Central
Loading ...
Support Center